Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.
Yubin Kang, MD
Advertisement
Articles by Yubin Kang, MD
Advertisement
Latest Updated Articles
Dr. Kang on the Preclinical Activity of ABC294640 in Multiple MyelomaPublished: June 8th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5